"Wow, Check out this blast from the past from 2010 when Astellas Pharma Extends a Tender Offer for OSI Pharma Amid Weak Shareholder Response to the shares that values the U.S. cancer drug developer at $3.5 billion. Stay the course we still have a ways to go with our OCAT venture or should I say misadventure."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.